Navigation Links
USC and second sight announce European clinical trial for Argus II retinal implant
Date:2/15/2008

Boston, MA, February 15, 2008 USC and Second Sight Medical Products Inc, leading developers of retinal prostheses for treating blindness, announced today that they have completed enrollment of the first phase of a U.S .FDA approved clinical study of the Argus II Retinal Prosthesis System. They also announced that enrollment at key European sites is underway as studies continue in Mexico.

We are pleased that Second Sight, along with our fantastic clinical partners, was able to fully enroll the US trial in a timely manner, said Robert Greenberg, MD, PhD, President and CEO of Second Sight, and a leader in the field of retinal prostheses for more than 15 years.

Although it is too early to comment on the clinical data, each device continues to function as expected, and all participants are using their systems at home daily.

The Argus II is the second generation of an electronic retinal implant designed for the treatment of blindness due to Retinitis Pigmentosa (RP), a group of inherited eye diseases that affect the retina. The Argus II implant consists of an array of 60 electrodes that are attached to the retina. These electrodes conduct information acquired from an external camera to the retina to provide a rudimentary form of sight to implanted subjects.

The development of this technology was largely supported by the National Eye Institute (NEI) of the National Institutes of Health (NIH), and the Department of Energys Office of Science (DOE) Artificial Retina Project, which is helping to advance the implants design and construction. The unique resources and expertise at DOE national laboratoriesparticularly in engineering, microfabrication, material science, and microelectronic technologiesare enabling the development of much smaller, higher resolution devices.

Ten subjects were recruited for the Phase I trial at four leading ophthalmic centers throughout the US, including the Doheny Eye Institute at the University of Southern California (USC), Wilmer Eye Institute at Johns Hopkins University (Baltimore), the University of California at San Francisco, and the Retina Foundation of the Southwest (Dallas). Second Sight will be seeking expansion of the U.S. trial to include other trial sites located in New York (Columbia University Medical Center and Lighthouse International), Philadelphia (Scheie Eye Institute and Wills Eye Hospital) and Atlanta (Emory University and Atlanta V.A. Rehab R&D Center). This three-year Investigational Device Exemption (IDE) trial is the only long-term study of a retinal prosthesis currently being conducted anywhere in the world.

Internationally, the Argus II study began in Mexico in the fall of 2006 at Centro de Retina Medica y Quirurgica, SC, Centro Medico Puerta de Hierro, CUCS, Universidad de Guadalajara (Guadalajara, Jal.). More recently, enrollment has just begun at two European sites, including Service dOphtalmologie, Hpital Cantonal, Universitaire de Genve (Geneva, Switzerland) and Le Centre Hospitalier National DOphtalmologie Des Quinze-Vingts (Paris, France). A third study site at Moorfields Eye Hospital in London has recently received government approval and is expected to begin enrollment shortly.

The pioneering efforts of the individuals that participate in this clinical trial will lead to advances for the many people in the world afflicted with blindness, said Mark Humayun, MD, PhD, Professor of Ophthalmology, Biomedical Engineering, and Cellular and Neurobiology at the Doheny Eye Institute, Keck School of Medicine of USC, and Viterbi School of Engineering and the first physician to perform an Argus II implantation procedure in the US.

Dr. Humayun was the vitreo-retinal surgeon for the first generation 16-electrode (Argus 16), which he implanted in six RP subjects between 2002 and 2004. The study demonstrated the ability of participants to detect when lights are on or off, describe an objects motion, count discrete items, as well as locate and differentiate basic objects in an environment.

"We are excited about the progress being made in the development of this artificial retina technology," says Stephen Rose, PhD, Chief Research Officer, Foundation Fighting Blindness (FFB).

"FFB supported early preclinical studies of this technology, because of its great potential for giving vision to people with the most advanced retinal disease and we are pleased to have helped advance the prosthesis into critical clinical trials."


'/>"/>

Contact: Jon Weiner
jon.weiner@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Escalon(R) Reports Second Quarter Fiscal 2008 Results
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
8. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
9. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... Science Symposium (CSS) and the popularity of US Single Day Events (SDE) to ... in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... NEW YORK , Dec. 1, 2016   ... liquid photopurification, announced today that the Company has concluded ... has the right for a 90-day period to acquire ... invoice value of approximately USD 3.7 million.  ... an agreement with Tamarack under which Tamarack will seek ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... new moving magnet Voice Coil Actuator with a flexure design that ensures high ... life with cost-effective pricing and is ideally suited where extreme precision is required, ...
Breaking Biology Technology:
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
Breaking Biology News(10 mins):